Recent Updates
Recently added Catalysts
ICCC Positive Sentiment Score: 80/100

ImmuCell ImmuCell Hires Chief Financial Officer For Immediate Release

Key Takeaway: ImmuCell Corporation has appointed Timothy C. Fiori as its new Chief Financial Officer. Fiori, who has 24 years of experience from IDEXX Laboratories, looks forward to joining ImmuCell during a crucial phase of its development. Both Fiori and ImmuCell's President, Michael F. Brigham, emphasize the importance of his leadership in enhancing the company's growth strategies and operational efficiencies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Hiring Timothy C. Fiori brings extensive experience to the leadership team.
  • Fiori expresses excitement about contributing to ImmuCell's growth.
  • The company has a product portfolio with proven value and great potential.

Full Press Release Details

ImmuCell Hires Chief Financial Officer
PORTLAND, Maine - April 7, 2025 - ImmuCell
Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops,
manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle,
today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer.
Mr. Fiori brings to ImmuCell approximately 24 years of finance and
commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 graduate of the University of Maine, Orono with
a B.S in Finance. He lives in Raymond, Maine with his wife, Rachel, and enjoys many outdoor activities.
"I am excited to join the ImmuCell leadership team at such a
pivotal time in the Company's development," commented Mr. Fiori. "The product portfolio has tremendous proven value
and great potential as we look to the future. I'm eager to start contributing immediately to the Company's growth and development."
"Adding Tim's depth of experience and his great attitude
to our team is a critical step in our ongoing growth plan," added Michael F. Brigham, President and CEO. "He can help us leverage
our personnel, improve our standard costing and financial reporting systems and find new efficiencies in all aspects of our business,
to touch on just a few of the anticipated impacts that I believe Tim will have on our business."
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically
proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets
First Defense , providing Immediate Immunity to newborn dairy and beef calves, and is in the late
stages of developing Re-Tain , a novel treatment for subclinical mastitis in dairy cows without FDA-required milk
discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional antibiotics. Press releases and other
information about the Company are available at: http://www.immucell.com.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor
This Press Release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can
be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as "expects",
"may", "anticipates", "aims", "intends", "would", "could", "should",
"will", "plans", "believes", "estimates", "targets", "projects",
"forecasts", "seeks" and similar words and expressions. Such statements include, but are not limited to, any forward-looking
statements relating to: our plans, goals and strategies for our business; future improvements to internal financial and accounting systems;
projections of future financial or operational performance; future demand for our products; the timing and outcome of pending or anticipated
applications for regulatory approvals; and any other statements that are not historical facts. These statements are intended to provide
management's current expectations of future events as of the date of this earnings release, are based on management's estimates, projections,
beliefs and assumptions as of the date hereof and are not guarantees of future performance. Such statements involve known and unknown
risks and uncertainties that may cause the Company's actual results, financial or operational performance or achievements to be materially
different from those expressed or implied by these forward-looking statements; forward-looking statements include other risks and uncertainties
detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q,
our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based on
our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that
future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking
statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or
Contacts: Michael F. Brigham, President and CEO
ImmuCell Corporation
(207) 878-2770
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
(602) 889-9700
iccc@lythampartners.com

Frequently Asked Questions

Who has been hired as ImmuCell's new CFO?

ImmuCell has appointed Timothy C. Fiori as its Chief Financial Officer.

What is the main focus of ImmuCell's products?

ImmuCell develops products aimed at enhancing health and productivity in cattle.

How long has Timothy Fiori worked in finance?

Timothy Fiori brings 24 years of finance experience to ImmuCell.

What is ImmuCell's notable product for newborn calves?

ImmuCell's First Defense provides immediate immunity to newborn calves.

Where did Timothy Fiori graduate from?

Timothy Fiori graduated from the University of Maine, Orono, in 2001.

Last updated: Apr 7, 2025